Phase I study of E7820, an oral inhibitor of integrin α-2 expression with antiangiogenic properties, in patients with advanced malignancies

Monica Mita*, Kevin R. Kelly, Alain Mita, Alejandro D. Ricart, Ofelia Romero, Anthony Tolcher, Laurel Hook, Chukwuemeka Okereke, Ilya Krivelevich, Daniel P. Rossignol, Francis J. Giles, Eric K. Rowinsky, Chris Takimoto

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

31 Scopus citations

Fingerprint

Dive into the research topics of 'Phase I study of E7820, an oral inhibitor of integrin α-2 expression with antiangiogenic properties, in patients with advanced malignancies'. Together they form a unique fingerprint.

Medicine & Life Sciences